Evrópusambandið - ítalska - EMA (European Medicines Agency)

eli lilly nederland b.v. - olanzapina - schizophrenia; bipolar disorder - psicolettici - adultsolanzapine è indicato per il trattamento della schizofrenia. olanzapina è efficace nel mantenere il miglioramento clinico durante il proseguimento della terapia in pazienti che hanno mostrato una risposta al trattamento iniziale. olanzapina è indicata per il trattamento di moderata a grave episodio maniacale. nei pazienti in cui l'episodio maniacale ha risposto al trattamento con olanzapina, l'olanzapina è indicata per la prevenzione delle recidive nei pazienti con disturbo bipolare.

Ítalía - ítalska - AIFA (Agenzia Italiana del Farmaco)

abacus medicine a/s - nivolumab - nivolumab

Ítalía - ítalska - AIFA (Agenzia Italiana del Farmaco)

gekofar s.r.l. - nivolumab - nivolumab

Sviss - ítalska - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - olanzapinum - orale compresse morbide - olanzapinum 5 mg, gelatina, mannitolum 4,5 mg, aspartamum 600 µg, propylis parahydroxybenzoas natricus 37.5 mg, e 219 113 µg, per compresso corrisp. sodio 19 µg. - neuroleptique - synthetika

Sviss - ítalska - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - olanzapinum - orale compresse morbide - olanzapinum 10 mg, gelatina, mannitolum 6 mg, aspartamum 800 µg, propylis parahydroxybenzoas natricus 50 µg, e 219 150 µg, per compresso corrisp. sodio 26 µg. - neuroleptique - synthetika

Sviss - ítalska - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - olanzapinum - orale compresse morbide - olanzapinum 15 mg, gelatina, mannitolum 9 mg, aspartamum 1,2 mg, propylis parahydroxybenzoas natricus 75 µg, e 219 225 µg, per compresso corrisp. sodio 38 µg. - neuroleptique - synthetika

Sviss - ítalska - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - olanzapinum - orale compresse morbide - olanzapinum 20 mg, gelatina, mannitolum 12 mg, aspartamum 1,6 mg, propylis parahydroxybenzoas natricus 100 µg, e 219 300 µg, per compresso corrisp. sodio 51 µg. - neuroleptique - synthetika

Ítalía - ítalska - Ministero della Salute

fresenius vial sas - pompe d'infusione

Ítalía - ítalska - Ministero della Salute

fresenius vial sas - pompe d'infusione

Evrópusambandið - ítalska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - agenti antineoplastici - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 e 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.